Exhibit 99.1

[LOGO OF ANTARES PHARMA, INC.]

Contact Information

Dr. Roger Harrison      CEO                                     (610) 458-6200
Lawrence M. Christian   Vice President - Finance / CFO          (610) 458-6200
Robert Bauer            Investor Relations, Bluefire Partners   (612) 344-1016


               MAJORITY SHAREHOLDER CONVERTS SHORT-TERM LOAN INTO
                          COMMON STOCK AT MARKET PRICE

Exton, Pennsylvania -- June 25, 2002 -- Antares Pharma, Inc. (Nasdaq: ANTR)
today announced that its major shareholder, Dr. Jacques Gonella, has converted
the $2 million term note from the Company into Antares Pharma common stock at
the market price as of June 10, 2002. The Company's Board of Directors approved
this transaction at its June 20, 2002, meeting.

     Dr. Gonella stated, "I am pleased with the continuing development of this
young company. I speak on behalf of the Board in saying that Antares Pharma, led
by its able management team, has made enormous strides in establishing business
relationships and in sharing its vision with stakeholders. My confidence in the
future is reflected in my decision to convert my $2 million term note into
stock."

     Dr. Roger G. Harrison, CEO and President of Antares Pharma, added, "We
appreciate Dr. Gonella's continued confidence in Antares Pharma. We look forward
to continue building on the momentum we have established in 2002 and delivering
on our plan for the year."

About Antares Pharma
Antares Pharma develops pharmaceutical delivery systems, including needle-free
and mini-needle injector systems and transdermal gel technologies. These
delivery systems are designed to improve both the efficiency of drug therapies
and the patient's quality of life. The Company currently distributes its
needle-free injector systems for the delivery of insulin and growth hormone in
more than 20 countries and an estradiol transdermal patch for hormone
replacement therapy. In addition, Antares Pharma has five products under
development and is conducting ongoing research to create new products that
combine various elements of the Company's technology portfolio. Antares Pharma
has corporate headquarters in Exton, Pennsylvania, with production and research
facilities in Minneapolis, Minnesota, and research facilities in Basel,
Switzerland.

     Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could case
actual results to differ materially and which are identified from time to time
in the Company's reports filed with the U.S. Securities and Exchange Commission.
Antares Pharma claims the protection of the Safe Harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma's web site at www.antarespharma.com.
                                                         ---------------------

                                      # # #

                                 Exhibit 99.1-1